Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia
- PMID: 11245484
Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia
Abstract
We identified TMPRSS2 as a gene that is down-regulated in androgen-independent prostate cancer xenograft tissue derived from a bone metastasis. Using specific monoclonal antibodies, we show that the TMPRSS2-encoded serine protease is expressed as a Mr 70,000 full-length form and a cleaved Mr 32,000 protease domain. Mutation of Ser-441 in the catalytic triad shows that the proteolytic cleavage is dependent on catalytic activity, suggesting that it occurs as a result of autocleavage. Mutational analysis reveals the cleavage site to be at Arg-255. A consequence of autocatalytic cleavage is the secretion of the protease domain into the media by TMPRSS2-expressing prostate cancer cells and into the sera of prostate tumor-bearing mice. Immunohistochemical analysis of clinical specimens demonstrates the highest expression of TMPRSS2 at the apical side of prostate and prostate cancer secretory epithelia and within the lumen of the glands. Similar luminal staining was detected in colon cancer samples. Expression was also seen in colon and pancreas, with little to no expression detected in seven additional normal tissues. These data demonstrate that TMPRSS2 is a secreted protease that is highly expressed in prostate and prostate cancer, making it a potential target for cancer therapy and diagnosis.
Similar articles
-
The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.J Pathol. 2008 Jun;215(2):118-25. doi: 10.1002/path.2330. J Pathol. 2008. PMID: 18338334
-
Regulation of expression of Na+,K+-ATPase in androgen-dependent and androgen-independent prostate cancer.Br J Cancer. 1999 Sep;81(1):28-36. doi: 10.1038/sj.bjc.6690647. Br J Cancer. 1999. PMID: 10487609 Free PMC article.
-
Evolution of the androgen receptor pathway during progression of prostate cancer.Cancer Res. 2006 May 15;66(10):5012-20. doi: 10.1158/0008-5472.CAN-05-3082. Cancer Res. 2006. PMID: 16707422
-
Androgen receptor and prostate cancer: molecular aspects and gene expression profiling.Curr Opin Drug Discov Devel. 2003 Sep;6(5):702-11. Curr Opin Drug Discov Devel. 2003. PMID: 14579520 Review.
-
Molecular regulation of androgen action in prostate cancer.J Cell Biochem. 2006 Oct 1;99(2):333-44. doi: 10.1002/jcb.20794. J Cell Biochem. 2006. PMID: 16518832 Review.
Cited by
-
A survey of genetic variants in SARS-CoV-2 interacting domains of ACE2, TMPRSS2 and TLR3/7/8 across populations.Infect Genet Evol. 2020 Nov;85:104507. doi: 10.1016/j.meegid.2020.104507. Epub 2020 Aug 26. Infect Genet Evol. 2020. PMID: 32858233 Free PMC article.
-
The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells.Biochem J. 2005 Jun 15;388(Pt 3):967-72. doi: 10.1042/BJ20041066. Biochem J. 2005. PMID: 15537383 Free PMC article.
-
Computational and in vitro experimental analyses of the anti-COVID-19 potential of Mortaparib and MortaparibPlus.Biosci Rep. 2021 Oct 29;41(10):BSR20212156. doi: 10.1042/BSR20212156. Biosci Rep. 2021. PMID: 34647577 Free PMC article.
-
Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.J Biomol Struct Dyn. 2022 Jan;40(1):1-13. doi: 10.1080/07391102.2020.1775704. Epub 2020 Jun 16. J Biomol Struct Dyn. 2022. PMID: 32469279 Free PMC article.
-
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.Lancet. 2020 Jun 20;395(10241):1907-1918. doi: 10.1016/S0140-6736(20)31187-9. Epub 2020 May 28. Lancet. 2020. PMID: 32473681 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Molecular Biology Databases